Previous close | 0.0500 |
Open | N/A |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 7.50 |
Expiry date | 2024-06-21 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 1 |
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in the TD Cowen 5th Annual Oncology Innovation Summit. TD Cowen 5th Annual Oncology Innovation SummitTuesday, May 28, 20249:30am PT/12:30pm ET The webcast will be posted to the Company's website at www.allogene.com
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
Exploring Allogene's Q1 performance, strategic initiatives in oncology, and financial maneuvers amidst a challenging landscape.